Population pharmacokinetics and dosing of long-acting injectable antipsychotics

David D. Kim, MSc; Alasdair M. Barr, PhD; Reza Rafizadeh, BScPharm; Ric M. Procyshyn, PhD

A 29-year-old man with schizophrenia treated with aripiprazole 15 mg/d visited his psychiatrist accompanied by his mother, who mentioned that although her son is doing well, she must remind him to take his medication. The psychiatrist offered the patient injectable aripiprazole once monthly (AOM), and he agreed. The psychiatrist recently learned that Health Canada approved a new initiation regimen consisting of 2 separate intramuscular (IM) injections of 400 mg and a single 20 mg dose of oral aripiprazole.1,2 However, the psychiatrist is uncomfortable with this initiation regimen because it was based on simulations, not traditional pharmacokinetics (PK).

Most clinicians are familiar with traditional PK studies, which are generally performed in Phase I of drug development. Conversely, many clinicians are not likely familiar with population PK (PopPK), a study of quantifying factors responsible for variability in drug concentrations among individuals who are the target population for the drug.3-5 Unfortunately, PopPK is often viewed with skepticism by clinicians unfamiliar with its validity,4 although government agencies approve its utility to inform drug use. Both traditional PK and PopPK have advantages and disadvantages (Table 1).3

There are 4 basic steps in PopPK. Step 1 is data collection. Some data may come from small, traditional PK studies but, by far, most data are obtained from Phase 2 and 3 efficacy/tolerability clinical trials using actual patients for whom the drug was intended. Step 2 is developing a model that best explains the data (e.g., a 2-compartment model with first-order absorption for IM injection). Step 3 is model validation. In simple terms, the model must be validated using various techniques including diagnostic plots or prediction-corrected visual predictive checks. Once the model has been validated, simulations (step 4) can be performed.

PopPK analyses have been approved by Health Canada for the initiation regimens of paliperidone palmitate (PP1M) and AOM. In the case of PP1M, the data for PopPK analyses come from 11 clinical trials (n = 1795), resulting in 18 530 paliperidone plasma concentrations.5 Several simulations were performed before choosing the approved initiation regimen of 150 mg (day 1) and 100 mg (day 8) given by IM administration via the deltoid muscle. PopPK analyses were also used to provide guidance regarding missed doses, CYP2D6 phenotype, race and smoking status.6

Similarly, PopPK was used to determine an alternative initiation regimen of AOM. The data for PopPK analyses come from 7 clinical trials (n = 817), resulting in 8214 aripiprazole plasma concentrations.7 Various simulations were performed, and a 2-injection initiation regimen was approved by Health Canada as follows: 2 separate injections of 400 mg AOM at separate injection sites and a single 20 mg dose of oral aripiprazole. PopPK analyses also supplement the product monograph to guide dosing with regards to ethnic origin; smoking status; dosage adjustments for poor metabolizers of CYP2D6 and patients taking concomitant CYP2D6 and/or CYP3A4 inhibitors; and missed doses.2 Following the 2-injection start, single monthly doses of AOM 400 mg are given.

Although the patient in our case was on 15 mg of oral aripiprazole, the product monograph (based on PopPK simulations) states that a single 20 mg dose of oral aripiprazole should be used with the 2-injection start, irrespective of the previous dose of oral aripiprazole or any other antipsychotic. The product monograph also states that the existing oral antipsychotic should be discontinued immediately following the 2-injection start. However, clinicians should use their judgment, as it may be better to gradually taper patients off the previous (nonaripiprazole) antipsychotic to prevent withdrawal reactions.

| Table 1: Advantages and disadvantages of traditional and population pharmacokinetics |
|-----------------------------------------------|-----------------------------------------------|
| **Advantages** | **Disadvantages** |
| **Traditional PK** | | |
| Small numbers of participants required (usually < 20) | Often done in “healthy” participants rather than the target patient population |
| Minimizes interindividual variability via fixed, restrictive sampling designs | Multiple blood samples required from each participant |
| Simple PK modelling and calculations | Cannot handle sparse sampling or identify covariates affecting variability in drug concentrations |
| **Population PK** | | |
| Often done in patients for whom the drug was intended | Large clinical samples required |
| Accommodates flexible study designs, handles sparse sampling, and requires few blood samples from each patient | Entails handling large amounts of data |
| Quantifies covariates accounting for interindividual PK variability (e.g., age, weight, smoking, concomitant medications) | Complex statistical analyses (e.g., model building, diagnostics, missing data treatment) |

PK = pharmacokinetic.
Clinicians should be aware that approved dosing strategies for many drugs used in various therapeutic areas were based on PopPK analyses. However, it is also important to recognize that although PopPK explains variability in drug concentration among individuals, it does not help predict potential adverse events. Further education on PopPK will help to increase awareness of its role in drug development and dosing optimization.

Affiliations: From the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia (Kim, Barr); the British Columbia Mental Health & Substance Use Services Research Institute (Kim, Barr, Procyshyn); the Lower Mainland Pharmacy Services and Faculty of Pharmaceutical Sciences, University of British Columbia (Rafizadeh); and the Department of Psychiatry, University of British Columbia (Procyshyn), Vancouver, BC, Canada.

Competing interests: R.M. Procyshyn has received consulting fees or sat on paid advisory boards for Janssen, Lundbeck and Otsuka and is on the speakers bureau for Eisai, Janssen, Lundbeck and Otsuka. No other competing interests were declared.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Cite as: J Psychiatry Neurosci 2021 September 1;46(5). doi: 10.1503/jpn.210079

References
1. Otsuka Canada. Health Canada approves Otsuka and Lundbeck’s ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) alternative initiation regimen. Cision Ltd; 2021 Mar. 3. Available: https://www.newswire.ca/news-releases/health-canada-approves-otsuka-and-lundbeck-s-abilify-maintena-r-aripiprazole-for-prolonged-release-injectable-suspension-alternative-initiation-regimen-850848524.html (accessed 2021 Apr. 7).
2. Otsuka Pharmaceutical Co., Ltd. Product Monograph of ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension). 2014 Jun. 29 [revised 2020 Jan. 24]. In: Health Canada Drug Product Database. Toronto: Otsuka Pharmaceutical Co., Ltd. Available: https://pdf.hres.ca/dpd_pm/00060200.PDF (accessed 2021 Apr. 7).
3. Charles B. Population pharmacokinetics: an overview. Aust Prescr 2014;37:210-3.
4. Duffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses — a clinical viewpoint. Br J Clin Pharmacol 2011;71: 807-14.
5. Center for Drug Evaluation and research. Application Number: 22-264, Clinical Pharmacology and Biopharmaceutics Review(s). US Food and Drug Administration; 2009 Feb. 3. Available: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000clindraftpmr.pdf (accessed 2021 Apr. 7).
6. Janssen Inc. Product monograph of INVEGA SUSTENNA (paliperidone palmitate Prolonged-Release Injectable Suspension, paliperidone as paliperidone palmitate). 2010 Jun. 29 [revised 2020 Jan. 24]. In: Health Canada Drug Product Database. Toronto: Janssen Inc. Available: https://pdf.hres.ca/dpd_pm/00059297.PDF (accessed 2021 Apr. 7).
7. Wang Y, Want X, Harlin M, et al. The two-injection start of aripiprazole once-monthly provides rapid attainment of therapeutic concentrations without the need for 14-day oral tablet supplementation. Poster presented at: the European College of Neuropsychopharmacology (ECNP) Congress; 2020 Sept. 12-15; virtual.